French IT services company providing infrastructure management, consulting and outsourcing to mid-size and large enterprises.
French IT services company providing infrastructure management, consulting and outsourcing to mid-size and large enterprises.
Sells staff time and managed services: infrastructure outsourcing contracts bill for running a client's systems over several years, while consulting and software-engineering work is billed by the day. Growth has come partly from buying small firms and keeping them as semi-independent subsidiaries.
In one line: A smaller French IT-services firm like a mini Sopra Steria.
Moat: none (installed base). Solid regional IT-services relationships but no structural advantage over larger, better-resourced peers.
Headquarters: Levallois-Perret, France · Founded: 1985 · Employees: 7,208
Size Neurones (NRO.PA) is a France Industrials company (Miscellaneous Commercial Services) with a market value of $1.03B, the 137th largest of 206 France companies the cockpit tracks. Shares closed at €39.40 on 18 Nov 2026.
Performance Over six months the shares gained 3.3%, against -13.9% for the median peer and -2.1% for the France market (cap-weighted) — 6th highest of 21 in its peer set.
Growth Revenue grew 6.7% over the last twelve months (peer median +6.9%); the operating margin is 8.9% (peer median 10.4%).
Valuation It trades at 16.9× forward earnings against a peer median of 16.7× (9th most expensive of 18).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -18 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 18.0 points above its cost of capital (7.5% WACC).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | €888M | €857M | €810M | €741M | €665M |
| Revenue growth | — | +6% | +9% | +11% | — |
| Gross profit | €97.5M | €90.0M | €89.3M | €86.4M | €81.6M |
| EBITDA | €96.3M | €90.3M | €93.3M | €89.0M | €86.3M |
| Net income | €55.2M | €52.1M | €52.6M | €49.4M | €44.2M |
| Free cash flow | €88.6M | €70.3M | €82.5M | €59.0M | €44.3M |
| Capital expenditure | €12.2M | €10.4M | €12.0M | €18.0M | €10.6M |
| Total debt | n/a | €37.0M | €42.0M | €44.0M | €35.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Neurones NRO.PA | $1.03B | +3% | +7% | 9% | 16.9× | -7.9% |
| Sopra Steria SOP.PA | $3.93B | +32% | +2% | 9% | 10.6× | -1.4% |
| Atos ATO.PA | $482M | -49% | -14% | 6% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | NRO.PA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.7% | -7.9% | 2nd highest of 21 |
| 6-month return | +3.3% | -13.9% | 6th highest of 21 |
| Distance from 52-week high | -12.4% | -36.7% | 2nd highest of 21 |
| Revenue growth (TTM) | +6.7% | +6.9% | 11th highest of 21 |
| Operating margin | 8.9% | 10.4% | 9th lowest of 21 |
| Forward P/E | 16.9× | 16.7× | 9th most expensive of 18 |
| Growth the price implies (Req g, 7 yrs) | -7.9% | 3.4% | 2nd least demanding of 10 |
| Growth delivered (Del g) | +10.3% | +8.8% | 5th highest of 10 |
| Hurdle (Req g minus delivered) | -18.3 pp | -10.0 pp | 3rd least demanding of 10 |
| ROIC minus cost of capital | +18.0 pp | -0.5 pp | 2nd highest of 19 |
| EV / EBITDA | 7.6× | 8.7× | 4th cheapest of 9 |
| Net debt / EBITDA | -2.7× | 0.5× | 2nd least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Neurones NRO.PA | France | $1.03B | +3% | +7% | 9% | 16.9× | -7.9% | +10.3% |
| DOOSAN TESNA 131970.KS | South Korea | $1.03B | -62% | +5% | 10% | 43.1× | n/a | n/a |
| Service Stream SSM.AX | Australia | $1.03B | -9% | +1% | 3% | 16.7× | 13.9% | +24.0% |
| Naruida Technology 688522.SS | China | $1.01B | -32% | +20% | 14% | 19.6× | n/a | n/a |
| Bajaj Mobility BMAG.SW | Switzerland | $1.05B | +40% | -47% | -44% | 8.9× | n/a | n/a |
| SBT Ultrasonic Technology 688392.SS | China | $1.06B | -36% | +42% | 17% | 49.3× | n/a | n/a |
| EMTEK (Shenzhen) 300938.SZ | China | $1,000M | -54% | +11% | 27% | 28.5× | n/a | n/a |
| Prosegur Cash CASH.MC | Spain | $1.07B | +10% | -2% | 11% | 9.6× | -12.1% | +5.7% |
| Smartgroup SIQ.AX | Australia | $986M | -6% | +10% | 37% | 14.7× | -1.3% | +8.8% |
| GL events GLO.PA | France | $986M | -13% | +6% | 10% | 8.8× | 3.4% | +29.1% |
| Shanghai Action Education Tehnology 605098.SS | China | $981M | -10% | +15% | 40% | 16.1× | -3.1% | +16.4% |
| Rites RITES.NS | India | $979M | -7% | +11% | 19% | 20.9× | 19.6% | +5.3% |
| Beijing Cuiwei Tower 603123.SS | China | $978M | -26% | -12% | -18% | n/a | n/a | n/a |
| Graincorp GNC.AX | Australia | $976M | +41% | -2% | -1% | 21.9× | n/a | n/a |
| China East Education 0667.HK | Hong Kong | $1.09B | -21% | +16% | 22% | 7.8× | -7.5% | +4.1% |
| FESCO 600861.SS | China | $1.10B | -15% | +4% | 1% | 10.5× | n/a | n/a |
| Zhejiang Meorient Commerce & Exhibition 300795.SZ | China | $962M | +16% | -3% | 18% | 39.6× | n/a | n/a |
| Vcanbio Cell & Gene Engineering 600645.SS | China | $1.11B | -29% | -6% | 12% | 40.7× | 8.9% | +1.9% |
| Shenzhen Aoni Electronic 301189.SZ | China | $949M | -45% | +139% | 2% | n/a | n/a | n/a |
| Suzhou Novoprotein Scientific 688137.SS | China | $1.12B | +117% | +8% | -62% | n/a | n/a | n/a |
| Willdan WLDN | United States | $1.13B | -20% | +19% | 7% | 14.6× | 17.2% | +11.8% |